J
Justine A. Barletta
Researcher at Brigham and Women's Hospital
Publications - 136
Citations - 9391
Justine A. Barletta is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Thyroid carcinoma & Thyroid cancer. The author has an hindex of 40, co-authored 121 publications receiving 7609 citations. Previous affiliations of Justine A. Barletta include University of California, San Francisco & Harvard University.
Papers
More filters
Journal ArticleDOI
Characterizing the cancer genome in lung adenocarcinoma
Barbara A. Weir,Barbara A. Weir,Michele S. Woo,Gad Getz,Sven Perner,Sven Perner,Li Ding,Rameen Beroukhim,Rameen Beroukhim,William M. Lin,William M. Lin,Michael A. Province,Aldi T. Kraja,Laura A. Johnson,Kinjal Shah,Kinjal Shah,Mitsuo Sato,Roman K. Thomas,Justine A. Barletta,Ingrid B. Borecki,Stephen R. Broderick,Andrew C. Chang,Derek Y. Chiang,Derek Y. Chiang,Lucian R. Chirieac,Jeonghee Cho,Yoshitaka Fujii,Adi F. Gazdar,Thomas J. Giordano,Heidi Greulich,Heidi Greulich,Megan Hanna,Megan Hanna,Bruce E. Johnson,Mark G. Kris,Alex E. Lash,Ling Lin,Neal I. Lindeman,Elaine R. Mardis,John Douglas Mcpherson,John D. Minna,Margaret Morgan,Mark Nadel,Mark Nadel,Mark B. Orringer,John R. Osborne,Brad Ozenberger,Alex H. Ramos,Alex H. Ramos,James T. Robinson,Jack A. Roth,Valerie W. Rusch,Hidefumi Sasaki,Frances A. Shepherd,Carrie Sougnez,Margaret R. Spitz,Ming-Sound Tsao,David Twomey,Roel G.W. Verhaak,George M. Weinstock,David A. Wheeler,Wendy Winckler,Wendy Winckler,Akihiko Yoshizawa,Soyoung Yu,Maureen F. Zakowski,Qunyuan Zhang,David G. Beer,Ignacio I. Wistuba,Mark A. Watson,Levi A. Garraway,Levi A. Garraway,Marc Ladanyi,William D. Travis,William Pao,Mark A. Rubin,Mark A. Rubin,Stacey Gabriel,Richard A. Gibbs,Harold E. Varmus,Richard K. Wilson,Eric S. Lander,Eric S. Lander,Eric S. Lander,Matthew Meyerson,Matthew Meyerson +85 more
TL;DR: A large-scale project to characterize copy-number alterations in primary lung adenocarcinomas using dense single nucleotide polymorphism arrays identifies NKX2-1 (NK2 homeobox 1, also called TITF1), which lies in the minimal 14q13.3 amplification interval and encodes a lineage-specific transcription factor, as a novel candidate proto-oncogene involved in a significant fraction of lung carcinomas.
Journal ArticleDOI
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors
Yuri E. Nikiforov,Raja R. Seethala,Giovanni Tallini,Zubair W. Baloch,Fulvio Basolo,Lester D.R. Thompson,Justine A. Barletta,Bruce M. Wenig,Abir Al Ghuzlan,Kennichi Kakudo,Thomas J. Giordano,Venancio Avancini Ferreira Alves,Elham Khanafshar,Sylvia L. Asa,Adel K. El-Naggar,William E. Gooding,Steven P. Hodak,Ricardo V. Lloyd,Guy Maytal,Ozgur Mete,Marina N. Nikiforova,Vania Nosé,Mauro Papotti,David N. Poller,Peter M. Sadow,Arthur S. Tischler,R. Michael Tuttle,Kathryn B. Wall,Virginia A. LiVolsi,Gregory W. Randolph,Ronald Ghossein +30 more
TL;DR: Thyroid tumors currently diagnosed as noninvasive EFVPTC have a very low risk of adverse outcome and should be termed NIFTP, and this reclassification will affect a large population of patients worldwide and result in a significant reduction in psychological and clinical consequences associated with the diagnosis of cancer.
Journal ArticleDOI
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
Scott J. Rodig,Mari Mino-Kenudson,Sanja Dacic,Beow Y. Yeap,Alice T. Shaw,Justine A. Barletta,Hannah Stubbs,Kenneth Law,Neal I. Lindeman,Eugene J. Mark,Pasi A. Jänne,Thomas J. Lynch,Bruce E. Johnson,A. John Iafrate,Lucian R. Chirieac +14 more
TL;DR: Lung adenocarcinomas with ALK rearrangements are uncommon in the western population and represent a distinct entity of carcinomas with unique characteristics, and dual diagnostic testing, with FISH and immunohistochemistry, should be considered.
Journal ArticleDOI
Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
Eliezer M. Van Allen,Kent W. Mouw,Philip H. Kim,Gopa Iyer,Nikhil Wagle,Hikmat Al-Ahmadie,Cong Zhu,Irina Ostrovnaya,Gregory V. Kryukov,Kevin W O'Connor,John P. Sfakianos,Ilana Rebecca Garcia-Grossman,Jaegil Kim,Elizabeth A. Guancial,Richard Martin Bambury,Samira Bahl,Namrata Gupta,Deborah N. Farlow,Angela Qu,Sabina Signoretti,Justine A. Barletta,Victor E. Reuter,Jesse S. Boehm,Michael S. Lawrence,Gad Getz,Philip W. Kantoff,Bernard H. Bochner,Toni K. Choueiri,Dean F. Bajorin,David B. Solit,Stacey Gabriel,Alan D. D'Andrea,Levi A. Garraway,Levi A. Garraway,Jonathan E. Rosenberg,Jonathan E. Rosenberg +35 more
TL;DR: Somatic ERCC2 mutations correlate with complete response to cisplatin-based chemosensitivity in muscle-invasive urothelial carcinoma, and clinically identified mutations lead to cisPlatin sensitivity in vitro.
Journal ArticleDOI
A comprehensive analysis of PAX8 expression in human epithelial tumors.
Anna Laury,Ruth Perets,Huiying Piao,Jeffrey F. Krane,Justine A. Barletta,Christopher A. French,Lucian R. Chirieac,Rosina T. Lis,Massimo Loda,Jason L. Hornick,Ronny Drapkin,Michelle S. Hirsch +11 more
TL;DR: Results show that PAX8 is a highly sensitive marker for thyroid, renal, Müllerian, and thymic tumors, and is an excellent marker for confirming primary tumor site.